Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Mechanism of action of antidepressant medications
Autore:
Feighner, JP;
Indirizzi:
John P Feighner MD Inc, San Diego, CA USA John P Feighner MD Inc San Diego CA USA ighner MD Inc, San Diego, CA USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
, volume: 60, anno: 1999, supplemento:, 4
pagine: 4 - 13
SICI:
0160-6689(1999)60:<4:MOAOAM>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRUE DRUG RESPONSE; DOUBLE-BLIND; MAJOR DEPRESSION; PATTERN-ANALYSIS; PROTEIN-KINASE; VENLAFAXINE; FLUOXETINE; PLACEBO; NEFAZODONE; PHARMACOLOGY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
53
Recensione:
Indirizzi per estratti:
Indirizzo: Feighner, JP 5375 Mira Sorrento Pl,Suite 210, San Diego, CA 92121 USA 5375 Mira Sorrento Pl,Suite 210 San Diego CA USA 92121 1 USA
Citazione:
J.P. Feighner, "Mechanism of action of antidepressant medications", J CLIN PSY, 60, 1999, pp. 4-13

Abstract

The psychopharmacology of depression is a field that has evolved rapidly in just under 5 decades. Early antidepressant medications-tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs)-were discovered through astute clinical observations. These first-generation medications were effective because they enhanced serotonergic or noradrenergic mechanisms orboth. Unfortunately, the TCAs also blocked histaminic, cholinergic, and alpha(1)-adrenergic receptor sites, and this action brought about unwanted side effects such as weight gain, dry mouth, constipation, drowsiness, and dizziness. MAOIs can interact with tyramine to cause potentially lethal hypertension and present potentially dangerous interactions with a number of medications and over-the-counter drugs. The newest generation of antidepressants, including the single-receptor selective serotonin reuptake inhibitors (SSRIs) and multiple-receptor antidepressants venlafaxine, mirtazapine, bupropion, trazodone, and nefazodone, target one or more specific brain receptor sites without, in most cases, activating unwanted sites such as histamineand acetylcholine. This paper discusses the new antidepressants, particularly with regard to mechanism of action, and looks at future developments inthe treatment of depression.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/08/20 alle ore 08:12:59